328130

Lunit is a medical artificial intelligence company founded in 2013 that develops deep learning-based software for cancer screening and precision oncology. The company operates two main business segments: Cancer Screening, which provides AI-assisted detection and imaging biomarker solutions for early cancer diagnosis, and Oncology, which offers digital pathology analysis and biomarker quantification to support treatment decisions. Key products include the Lunit INSIGHT suite for chest X-ray, mammography, and digital breast tomosynthesis, as well as the Lunit SCOPE platform for analyzing tissue pathology slides to predict immunotherapy response. Lunit acquired Lunit International, Ltd. in 2024 to expand its breast cancer screening capabilities. The company serves medical institutions and pharmaceutical partners globally, with significant presence in the United States, Japan, and Europe. Lunit partners with major medical device manufacturers such as GE Healthcare, Philips, Fujifilm, and Hologic to distribute its software, and collaborates with biopharma companies like Guardant Health for oncology research and companion diagnostics.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage lunit.io
Sector Healthcare IR page lunit.io/en/investors
Tags
medical ai, cancer screening, precision oncology, digital pathology, imaging biomarkers, breast cancer detection, chest x-ray analysis, immunotherapy prediction, companion diagnostics, deep learning, Lunit INSIGHT, Lunit SCOPE, Lunit INSIGHT CXR, Lunit INSIGHT MMG, Lunit INSIGHT DBT, Lunit INSIGHT Risk, Lunit SCOPE PD-L1 TPS, Lunit SCOPE IO Pan Cancer, Lunit SCOPE uIHC, Lunit SCOPE Genotype Predictor, Lunit International Ltd., Volpara Health Technologies Ltd., Guardant360 TissueNext, Lunit INSIGHT CXR4
Press page —

Metrics

Valuation  
Market cap —
Market cap (USD) —
P/E —
PEG —
P/BV —
P/S —
P/OCF —
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE -31.4%
ROI -34.5%
ROIC -45.4%
Profit margin -57.0%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock —
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) —
Quality score -30.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Revenue 83.129B 54.18B 25.08B 13.866B 6.639B
Net profit -47.39B -82.421B -36.798B -39.118B -73.676B
Free cash flow -55.814B -70.974B -37.855B -55.825B -33.352B

Filed figures

Figure Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (KRW) 1.26B 3.32B 5.38B 19.1B 21.8B
↳ YoY growth +162.7% +62.3% +255.3% +14.0%
Borrowings, current (KRW) — — 0.00 52.8B 74.5B
Bonds payable (KRW) — — 0.00 52.8B 74.5B
Cash and deposits (KRW) 15.7B 14.5B 31.7B 52.4B 14.1B
Intangible assets (KRW) 448M 1.58B 1.67B 277B 279B
Right-of-use assets (KRW) 883M 20.9B 18.9B 17.3B 15.4B
Net debt (borrowings + leases - cash) (KRW) — — -31.7B 473M 60.3B
Cash flow detail
Operating cash flow (KRW) -32.7B -53B -36.5B -65.7B -55.2B
Purchases of property, plant and equipment (KRW) -627M -2.81B -1.38B -5.28B -639M
Purchases of intangible assets (KRW) -126M -1.16B -209M -1.4B -8.99B
Interest paid (cash effect) (KRW) -88.1M -107M -2.01B -1.66B -4.07B
Income taxes paid (cash effect) (KRW) — — -153M -281M 378M
Free cash flow (OCF - PPE - intangibles) (KRW) -33.5B -57B -38.1B -72.4B -64.8B
Income detail
Total comprehensive income (KRW) -74B -38.8B -36.7B -81.5B -47.8B
Comprehensive income to owners (KRW) -74B -38.8B -36.7B -81.5B -47.8B
Reported Mar 21, 2024 Mar 21, 2024 Mar 23, 2026 Mar 23, 2026 Mar 23, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

분기보고서 (2026.09) Bull 0 Bear 0 Routine
본점소재지변경 Bull 0 Bear 0 Routine
증권발행결과(자율공시) Bull 0 Bear 4 Financing

Prompts

Lunit (ticker 328130), listed in South Korea.

ETFs Holding Lunit

ETF Weight in ETF Shares Market value As of
DEXC 0.01% 2,537 $ 26.162K Nov 12, 2026
DFSE 0.00% 1,364 $ 14.066K Nov 12, 2026
DFAX 0.00% 11,327 $ 116.807K Nov 12, 2026
DFEM 0.00% 6,899 $ 71.145K Nov 12, 2026
DFAE 0.00% 2,260 $ 23.306K Nov 12, 2026